Zoladex 10.8 MG implant syrns
Ended Awarded Last action
- Contract number
- SPE2DR26FMEE5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,498
Award facts
- Contract value 100% obligated
- $10,498.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $10,498.20 to DMS Pharmaceutical Group Inc. on January 8, 2026, for the supply of Zoladex 10.8 mg implant syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will fulfill this firm fixed-price delivery order with an ultimate completion date of January 30, 2026. The award carries no set-aside designation, reflecting the company's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V initiative, which was established on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
As a regional prime vendor contractor under the $30.3 billion Pharmaceutical Prime Vendor Global Program Generation V acquisition strategy, DMS Pharmaceutical Group supplies a comprehensive range of pharmaceuticals and medical consumables to support Department of Defense healthcare operations globally. The company's extensive product portfolio includes branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables that serve military healthcare facilities worldwide. The Zoladex 10.8 mg implant delivery represents part of the company's established pharmaceutical supply capability, with performance on numerous prior delivery orders demonstrating its ability to fulfill the specialized requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FMEE5?
SPE2DR26FMEE5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FMEE5 worth?
The government has obligated $10,498 on SPE2DR26FMEE5.
Is contract SPE2DR26FMEE5 an order under another contract?
Yes. SPE2DR26FMEE5 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEE5 competed?
The extent of competition for SPE2DR26FMEE5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award